The FDA approved Mounjaro (tirzepatide) to reduce heart attack and stroke risk in adults with type 2 diabetes. Eli Lilly says it's the first dual GIP/GLP-1 drug proven to prevent these serious heart events.

• •FDA approved Mounjaro (tirzepatide) to reduce heart attack and stroke risk in type 2 diabetes adults
• •Lilly calls tirzepatide the first dual GIP/GLP-1 drug proven to prevent serious heart events
• •Approval is a label expansion for Mounjaro, which was already approved for type 2 diabetes

Eli Lilly will present new study results on Foundayo (an oral weight-loss and diabetes drug), Mounjaro, and retatrutide at a major diabetes conference. The Foundayo data showed it worked better than two competing pills for type 2 diabetes.

• •Lilly to present data on Foundayo, Mounjaro, and retatrutide at ADA's 86th Scientific Sessions
• •Foundayo data showed it worked better than two competing pills for type 2 diabetes

Eli Lilly's tirzepatide (Mounjaro) is now the best-selling drug in the world. The drug treats both diabetes and weight loss, and its sales have grown faster than any other medicine.

• •Eli Lilly's Mounjaro (tirzepatide) is now the world's top-selling drug
• •The drug treats both diabetes and weight loss
• •Sales have grown faster than any other medicine

Eli Lilly's Mounjaro (a tirzepatide weight-loss and diabetes drug) hit $8.7 billion in quarterly sales, making it one of the company's top-selling medicines. The drug has become a major moneymaker for Eli Lilly as demand for weight-loss treatments continues to grow.

• •Mounjaro hit $8.7 billion in quarterly sales
• •Mounjaro is now one of Lilly's top-selling drugs
• •Tirzepatide treats both weight loss and diabetes

Eli Lilly's Mounjaro (tirzepatide), a diabetes and weight-loss drug, became the world's best-selling medicine, beating out Keytruda. The milestone shows how fast demand for tirzepatide has grown in recent years.

• •Lilly's Mounjaro became the world's best-selling drug
• •Mounjaro passed Merck's Keytruda for the top spot
• •Tirzepatide treats both diabetes and weight loss

France fined drug companies €1.7 million for how they advertised Mounjaro and Wegovy to doctors and patients. The penalty focuses on breaking rules about what companies can claim in their marketing materials.

• •France fined drug firms €1.7 million over Mounjaro and Wegovy ads
• •Penalty targets marketing claims made to doctors and patients
• •Action covers both Lilly's Mounjaro and Novo's Wegovy